Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04229004 · ClinicalTrials.gov registry record · Phase 3
A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer
A Phase 3 study, sponsored by Pancreatic Cancer Action Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 502
- Enrollment target
NCT04229004: Completed Phase 3 study, sponsored by Pancreatic Cancer Action Network.
NCT04229004 is a Phase 3 study that has completed, run by Pancreatic Cancer Action Network. The registered enrollment target is 502 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04229004, a Phase 3 study, has completed, sponsored by Pancreatic Cancer Action Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 502 participants
- Enrollment target
Study Summary
Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer. Primary Objectives * To compare each investigational arm versus standard of care (SOC) for superiority in overall survival in first and/or second line metastatic ductal adenocarcinoma (metastatic pancreatic cancer) participants and determine which, if any, participants benefit from each investigational arm. Secondary Objectives * To determine short and long-term safety signals of each investigational arm in metastatic pancreatic cancer participants vs. SOC. * To determine progression-free survival (PFS) for each investigational arm vs. SOC. * To determine rates of overall response, CR, and PR; duration of overall response, CR or PR (whichever occurs first). * To determine rates of clinical benefit; duration of clinical benefit.
Primary Outcome
Overall survival (OS) is defined from the time of initiation of treatment until death due to any cause. Participants still alive at the time of an analysis will be considered censored at their date of last contact.
Interventions
- DRUG Gemcitabine combined with nab-paclitaxel
- DRUG Dose -mFOLFIRINOX
- DRUG Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel
- DRUG Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine
- DRUG Drug: Dose -SM-88
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 502 participants |
| Start Date | 2020-01-31 |
| Est. Completion | 2025-02-05 |
| Phase | Phase 3 |
What the finished NCT04229004 record still lists
NCT04229004 is an interventional study that assigns participants to a tested intervention. The registered 502 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 5 interventions - of which Gemcitabine combined with nab-paclitaxel is the first listed.
NCT04229004 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04229004 about?
NCT04229004 is a clinical study titled "A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer". Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer. Primary Objectives * To compare each investigational arm versus standard of care (SOC) for superiority in overall survival in first and/or second line meta...
What is the current status of trial NCT04229004?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 502 participants. The study started on 2020-01-31. Estimated completion is 2025-02-05.
What interventions are being tested in trial NCT04229004?
The interventions under investigation include: Gemcitabine combined with nab-paclitaxel (DRUG), Dose -mFOLFIRINOX (DRUG), Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel (DRUG), Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine (DRUG), Drug: Dose -SM-88 (DRUG).
Who is sponsoring clinical trial NCT04229004?
This trial is sponsored by Pancreatic Cancer Action Network, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04229004's enrollment target sits among peer trials
502 743rd of 2000 higher than 1,258 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05646381 · 502 participants · Phase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- NCT05897632 · 502 participants · NA
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
- NCT05143931 · 503 participants · NA
Avoid and Resist Strategies for Weight Management
- NCT04442022 · 501 participants · Phase 2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI